AIM2 and central nervous system cancer: Additionally, DNA methylation analysis demonstrated that the promoter methylation levels of AIM2, CASP1, CASP8, NLRP3, and ZBP1 are significantly lower in gliomas than in non-tumor brain tissues (Supplement Fig. 3D-U).